Full-Time

Director of Health Economics and Market Access

Endomechanical and Energy

Posted on 11/23/2025

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$160k - $276k/yr

+ Bonus + Long-Term Incentive

Cincinnati, OH, USA

Hybrid

Category
Business & Strategy (1)
Requirements
  • Advanced degree (MS, MPH, PhD, MHA, MBA) in health economics, outcomes research, or healthcare-related field is required.
  • A minimum of 7 years of experience in the healthcare industry is required.
  • Strong technical background in evidence-based medicine, health economics, reimbursement or health policy with a demonstrated track record of success is required.
  • Strong understanding of the healthcare environment, the external marketplace and market access requirements is required.
  • Demonstrated ability developing and executing market access strategies for market access and adoption is required.
  • Strong understanding of health economics, outcomes research, and analytical methods, e.g., statistics and economic modelling; awareness and use of new and evolving digital techniques (e.g., Machine Learning, Artificial Intelligence, Intelligent Automation) is required.
  • Ability to work from strategy development to execution and value creation in a dynamic organization including creating value strategies, development and deployment of evidence-supported claims, input to pricing strategy, models, tools and value-based programs aligned with evidence and business strategy throughout the product lifecycle is required.
  • A strong understanding of medical delivery systems, reimbursement, market access conditions and health policy trends in major global markets is required.
  • Solid knowledge of evidence needed to drive favorable reimbursement and market access is required.
  • Experience leading health economic or outcomes research studies from concept through publication (including management of research vendors or consultants) is preferred.
  • Demonstrated track record in working in a cross-functional, matrixed environment is preferred.
  • Global experience is highly desirable.
Responsibilities
  • Lead the design and implementation of health economics, pricing, and reimbursement research for their respective platforms.
  • Evaluate the economic value of products and therapies with clinical and quality of life outcomes data from clinical trials and/or epidemiology studies.
  • Support the development and execution of lifecycle economic evidence and market access strategies that enable market access and commercial success.
  • Represent the voice of external, non-clinical stakeholders, such as payers and providers; ensure that market access requirements are understood and built into the product pipeline through Target Product Profiles and value propositions that reflect the needs of non-clinical stakeholders for their respective platforms.
  • Lead market access activities that include but are not limited to assessing market access needs/trends and developing required market access strategies to optimize market access and commercial success.
  • Partner with regions and key geographies to ensure value messages are clearly cascaded and supported by appropriate tools and evidence.
  • Manage research activities that include but are not limited to the burden of illness, retrospective database studies, creation of global economic models and value messaging, patient-reported outcomes development and analysis, interpretation of economic, satisfaction and QoL endpoints and results, and training on dissemination tools.
  • Work collaboratively with regional HEMA teams to identify evidentiary requirements and potential barriers to access and to secure positive endorsement when applicable from HTA agencies.
Desired Qualifications
  • Previous experience working in the Medtech industry is preferred.
  • Experience leading health economic or outcomes research studies from concept through publication (including management of research vendors or consultants) preferred.
  • Demonstrated track record in working in a cross-functional, matrixed environment is preferred.
  • Global experience highly desirable.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI and RYBREVANT are driving near-term oncology growth.
  • IMAAVY and CAPLYTA expand J&J into rare immunology and neuropsychiatry.
  • The Firefly Bio acquisition adds a pan-KRAS oncology platform.

What critics are saying

  • STELARA biosimilar erosion is already cutting a major immunology franchise.
  • Firefly Bio's KRAS platform remains early and can fail clinically.
  • AI surgery and Shockwave launches face adoption, reimbursement, and execution risk.

What makes Johnson & Johnson unique

  • J&J focuses on Innovative Medicine and MedTech after spinning off Kenvue in 2023.
  • Its portfolio spans oncology, immunology, neuroscience, cardiovascular, and surgical robotics.
  • The company combines internal R&D with acquisitions like Abiomed, Shockwave, and Ambrx.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE